Healthcare
Aduhelm: Case Study on Paying for Health
In July, I wrote an article that criticized the newly authorized Alzheimer’s drug Aduhelm. Six months later, the market response is heartening and, in my opinion, a case study in what it will take to fix the way that we pay for healthcare in America. A review of the problem The FDA approved the first […]
-
Optimizing Surgical Outcomes
By Calvin E. Beyer
Innovative providers have distinguished themselves...
-
On COVID Vaccine: Do the Math
By Daniel Miller
Facing what the UN calls an "infodemic," the Surge...
-
Mental Health in Post-COVID Era
By Calvin E. Beyer
By 2030, depression will be the leading cause of l...
-
How Synthetic Data Aids in Healthcare
By Artsiom Balabanau
Using synthetic data means important analysis and ...
